Biomedical Engineering Reference
In-Depth Information
96. (2007) Vernakalant: RSD 1235, RSD-1235, RSD1235. Drugs R D 8:259-265
97. Billman GE (2003) RSD-1235. Cardiome. Curr Opin Investig Drugs 4:352-354
98. Fedida D (2007) Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.
Expert Opin Investig Drugs 16:519-532
99. Roy D, Rowe BH, Stiell IG et al (2004) A randomized, controlled trial of RSD1235, a novel
anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol
44:2355-2361
100. Goldstein RN, Khrestian C, Carlsson L et al (2004) Azd7009: a new antiarrhythmic drug
with predominant effects on the atria effectively terminates and prevents reinduction of
atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol
15:1444-1450
101. Persson F, Carlsson L, Duker G et al (2005) Blocking characteristics of hERG, hNav1.5, and
hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009.
J Cardiovasc Electrophysiol 16:329-341
102. Lofberg L, Jacobson I, Carlsson L (2006) Electrophysiological and antiarrhythmic effects of
the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the
acutely dilated right atrium of the rabbit in vitro. Europace 8:549-557
103. Crijns HJ, Van Gelder IC, Walfridsson H et al (2006) Safe and effective conversion of
persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm
3:1321-1331
104. Camm AJ, Pratt CM, Schwartz PJ et al (2004) Mortality in patients after a recent myocardial
infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for
risk stratification. Circulation 109:990-996
105. Pritchett EL, Marcello SR (2003) Azimilide for atrial fibrillation: clinical trial results and
implications. Card Electrophysiol Rev 7:215-219
106. Pritchett EL, Kowey P, Connolly S et al (2006) Antiarrhythmic efficacy of azimilide in
patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus
rhythm. Am Heart J 151:1043-1049
107. Hohnloser SH, Dorian P, Straub M et al (2004) Safety and efficacy of intravenously
administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter.
J Am Coll Cardiol 44:99-104
108. Franqueza L, Longobardo M, Vicente J et al (1997) Molecular determinants of
stereoselective bupivacaine block of hKv1.5 channels. Circ Res 81:1053-1064
109. Caballero R, Moreno I, Gonzalez T et al (2002) Putative binding sites for benzocaine on a
human cardiac cloned channel (Kv1.5). Cardiovasc Res 56:104-117
110. Arechiga IA, Barrio-Echavarria GF, Rodriguez-Menchaca AA et al (2008) Kv1.5 open
channel block by the antiarrhythmic drug disopyramide: molecular determinants of block.
J Pharmacol Sci 108:49-55
111. Decher N, Pirard B, Bundis F et al (2004) Molecular basis for Kv1.5 channel block: conserva-
tion of drug binding sites among voltage-gated K+ channels. J Biol Chem 279:394-400
112. Decher N, Kumar P, Gonzalez T et al (2006) Binding site of a novel Kv1.5 blocker: a “foot in
the door” against atrial fibrillation. Mol Pharmacol 70:1204-1211
113. Luzhkov VB, Nilsson J, Arhem P et al (2003) Computational modelling of the open-state Kv
1.5 ion channel block by bupivacaine. Biochim Biophys Acta 1652:35-51
114. Pirard B, Brendel J, Peukert S (2005) The discovery of Kv1.5 blockers as a case study for the
application of virtual screening approaches. J Chem Inf Model 45:477-485
115. Yang Q, Fedida D, Xu H et al (2010) Structure-based virtual screening and electrophysio-
logical evaluation of new chemotypes of Kv1.5 channel blockers. ChemMedChem
5:1353-1358
